Scientia Vascular Appoints Paul Fischer as Chief Commercial Officer to Spearhead New Era of Growth and Innovation
WEST VALLEY CITY, UT / ACCESSWIRE / February 21, 2024 / Scientia Vascular, an emerging company in the neurovascular medical...
Brain
Route 92 Medical Announces Completion of Enrollment in the SUMMIT MAX Clinical Trial
Randomized controlled trial designed to evaluate the safety and effectiveness of the Route 92 Medical 0.088” HiPoint Reperfusion Catheter, part...
BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
BURLINGTON, Mass. and JERUSALEM, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Harvard Eye Associates Now Offering iDose(R) TR as a New Treatment Option to Reduce Eye Pressure in Patients With Ocular Hypertension and Open-Angle Glaucoma
iDose® TR helps patients with glaucoma take long-term control of high eye pressureLAGUNA HILLS, CA / ACCESSWIRE / February 20,...
Masimo and UCHealth Announce a Clinical Monitoring Partnership to Improve Care with Telehealth
IRVINE, Calif. & DENVER--(BUSINESS WIRE)--Masimo (NASDAQ: MASI), a leading global provider of medical technology and automation solutions, and UCHealth, a...
Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its Lead Oncology Program
Global thought leaders join advisory team to focus on Mestag’s groundbreaking tertiary lymphoid structure (TLS) induction approach to treat solid...
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
Publication pinpoints triggering of cGAS/STING pathway to activate immune defense mechanisms, as well as potentiation of anti-PD-L1 immune-mediated tumor cell...
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
– ARV-102 is a novel oral PROTAC® protein degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2...
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research
- Additional new data demonstrate VY-TAU01, Voyager’s lead antibody targeting pathological tau, was well-tolerated and demonstrated favorable pharmacokinetics in non-human...
Director of Brain Resource Center Presents at 2024 Annual Meeting of the World Economic Forum (WEF) in Davos, Switzerland
Updating the Human Brain With Vital NeuroMANHATTAN, NY / ACCESSWIRE / February 17, 2024 / As the world continues to...
FSD Pharma Announces US ATM Offering
TORONTO, ON / ACCESSWIRE / February 16, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share
SAN FRANCISCO and SAN DIEGO, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”),...
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add...
Hemogenyx Pharmaceuticals PLC Announces CBR Brain Delivery
Chimeric Bait Receptors for Combatting Brain Cancers and Neurodegenerative Diseases Can Be Delivered via Programmed Microglial CellsLONDON, UK / ACCESSWIRE...
NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
On track to complete enrollment of the chronic cohort in Q2 2024Data readout from chronic cohort expected in Q3 2024Planning...
Tonix Drug Shown To Relieve Pain in Fibromyalgia Without Risk of Addiction
Non-opioid drug candidate from Tonix lowered pain and also improved sleep and fatigueLatest Phase 3 trial achieved primary endpoint (p=0.00005)Potential...
ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
Up to 16 million adults in the US are living with a neurological disease, the leading cause of physical and...
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel...
Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update
With the Response Rate increasing to 23%, MDNA11 continues to show compelling single-agent activity in the ABILITY-1 study amongst high-dose...
MyndTec Inc. Completes Third Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - February 13, 2024) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), an emerging player in...